World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
107
Citations
79244
World Ranking
6093
National Ranking
13

Overview

John F. Forbes is affiliated with the University of Limerick in Ireland and has a research portfolio primarily situated in the field of Medicine. Their work spans several subfields including Rehabilitation, Pulmonary and Respiratory Medicine, Neurology, Public Health, Environmental and Occupational Health, and Epidemiology.

The scientist has contributed notably to a range of topics, including:

  • Stroke Rehabilitation and Recovery
  • Acute Ischemic Stroke Management
  • Physical Activity and Health
  • Estrogen and related hormone effects
  • Advanced Breast Cancer Therapies
  • COVID-19 and healthcare impacts
  • Long-Term Effects of COVID-19

Notable recent papers by John F. Forbes include:

  • "Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants" (2020) published in Occupational and Environmental Medicine
  • "Occupation and risk of severe COVID-19: prospective cohort study of 120,075 UK Biobank participants" (2020) published in bioRxiv (Cold Spring Harbor Laboratory)
  • "The associations of sugar-sweetened, artificially sweetened and naturally sweet juices with all-cause mortality in 198,285 UK Biobank participants: a prospective cohort study" (2020) published in BMC Medicine
  • "Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) - study protocol for a randomised controlled trial" (2021) published in European Stroke Journal
  • "Association Between Walking Pace and Stroke Incidence" (2020) published in Stroke

John F. Forbes frequently publishes in journals such as Cancer Research, Age and Ageing, International Journal of Stroke, HRB Open Research, and Occupational and Environmental Medicine.

Frequent collaborators include:

  • Sara Hayes
  • Jill P. Pell
  • Carlos Celis-Morales
  • Naveed Sattar
  • Cathal Walsh

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

    C Focan;SM Steinberg;M Blichert-Toft;JF Forbes

  • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

    M Baum;A U Budzar;J Cuzick;J Forbes

  • Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

    Anthony Howell

  • Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

    Christina Davies;Hongchao Pan;Jon Godwin;Richard Gray

  • Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial.

    D J Adam;J D Beard;T Cleveland;J Bell

  • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

    Beat Thürlimann;Aparna Keshaviah;Alan S Coates

  • Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

    Jack Cuzick;Ivana Sestak;Michael Baum;Aman U Buzdar

  • Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms

    Charles Mccollum;J. T. Powell;A. R. Brady;L. C. Brown

  • Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

    M Baum;A Buzdar;J Cuzick;J Forbes

  • Overview of the main outcomes in breast-cancer prevention trials.

    J Cuzick;T Powles;U Veronesi;J Forbes

  • Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

    Alan S. Coates;Aparna Keshaviah;Beat Thürlimann;Henning Mouridsen

  • Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

    M Dowsett;JF Forbes;JF Forbes;Matti Hakama

  • Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

    RC Coombes;LS Kilburn;CF Snowdon;R Paridaens

  • Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

    Mitch Dowsett;Jack Cuzick;Jim Ingle;Alan Coates

  • Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

    Jack Cuzick;Mitch Dowsett;Silvia Pineda;Christopher Wale

  • Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

    Mitch Dowsett;Jack Cuzick;Christopher Wale;John Forbes

  • First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

    J Cuzick;J Forbes;R Edwards;M Baum

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

Frequent Co-Authors

Jack Cuzick
Jack Cuzick Queen Mary University of London
Alan S. Coates
Alan S. Coates University of Sydney
Anthony Howell
Anthony Howell University of Manchester
Richard D. Gelber
Richard D. Gelber Harvard University
Karen N. Price
Karen N. Price Frontier Science Foundation
Gordon D. Murray
Gordon D. Murray University of Edinburgh
Aron Goldhirsch
Aron Goldhirsch European Institute of Oncology
Mitch Dowsett
Mitch Dowsett Breast Cancer Research Foundation
Beat Thürlimann
Beat Thürlimann Kantonsspital St. Gallen
Marco Colleoni
Marco Colleoni European Institute of Oncology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine doesn't always mean following a traditional path. There are several accessible online degrees and certifications that support different roles in healthcare, making it easier for students to find a pathway that aligns with their goals and financial circumstances.

For those interested in advanced nursing roles, searching for the cheapest dnp program options can help you earn a Doctor of Nursing Practice degree without a significant financial burden. If pharmacy is your passion, pursuing an online pharmacy degree offers flexibility and affordability compared to traditional campus programs.

Beyond clinical roles, online schools for health information management give students the skills to handle patient records and maintain healthcare data integrity—an essential part of modern medicine. You can learn more about pursuing these degrees by researching online schools for health information management.

Additionally, those looking to enter the administrative side of healthcare can find affordable training by reviewing medical coding certification cost. This pathway is ideal for individuals seeking a flexible and in-demand healthcare career without extensive schooling.

Best Scientists Citing John F. Forbes

Trending Scientists